TScan Therapeutics (TCRX) News Today $1.44 +0.14 (+10.77%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.42 -0.01 (-1.04%) As of 04/17/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33April 11, 2025 | americanbankingnews.comTScan Therapeutics (NASDAQ:TCRX) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $9.00 price objective on shares of TScan Therapeutics in a research note on Tuesday.April 10, 2025 | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Receives "Buy" Rating from Needham & Company LLCApril 10, 2025 | americanbankingnews.comNeedham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)April 9, 2025 | markets.businessinsider.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Buy" by AnalystsShares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned an average recommendation of "Buy" from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average twelve-month price objApril 9, 2025 | marketbeat.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest UpdateTScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 1,900,000 shares, a decrease of 14.8% from the February 28th total of 2,230,000 shares. Based on an average trading volume of 433,800 shares, the days-to-cover ratio is currently 4.4 days. Approximately 4.4% of the shares of the stock are short sold.April 2, 2025 | marketbeat.comTScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comTScan Therapeutics appoints Camiolo as SVP, Market AccessMarch 27, 2025 | markets.businessinsider.comTScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market AccessMarch 27, 2025 | globenewswire.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Recommendation of "Buy" by BrokeragesTScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has received a consensus rating of "Buy" from the six research firms that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 1 year target price among analysts thaMarch 15, 2025 | marketbeat.comTScan Therapeutics' (TCRX) "Overweight" Rating Reiterated at Morgan StanleyMorgan Stanley restated an "overweight" rating and set a $10.00 price target on shares of TScan Therapeutics in a report on Friday.March 15, 2025 | marketbeat.comTScan Therapeutics assumed with an Overweight at Morgan StanleyMarch 14, 2025 | markets.businessinsider.comTScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestonesMarch 14, 2025 | uk.investing.comWedbush Equities Analysts Cut Earnings Estimates for TCRXTScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities researchers at Wedbush decreased their FY2025 earnings per share estimates for shares of TScan Therapeutics in a research note issued to investors on Wednesday, March 5th. Wedbush analyst D. Nierengarten now forecasts that the companMarch 10, 2025 | marketbeat.comQ2 EPS Estimate for TScan Therapeutics Lowered by AnalystTScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Investment analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for shares of TScan Therapeutics in a report released on Thursday, March 6th. HC Wainwright analyst A. Fein now anticipates that the company will poMarch 10, 2025 | marketbeat.comBarclays Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock PriceBarclays reduced their target price on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a report on Friday.March 8, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for TCRX FY2029 Earnings?TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities researchers at HC Wainwright issued their FY2029 EPS estimates for shares of TScan Therapeutics in a research note issued on Thursday, March 6th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of $0.44 peMarch 8, 2025 | marketbeat.comTScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025March 7, 2025 | seekingalpha.comTScan Therapeutics price target lowered to $3 from $14 at BarclaysMarch 7, 2025 | markets.businessinsider.comTScan Therapeutics (NASDAQ:TCRX) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of TScan Therapeutics in a research report on Thursday.March 7, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for TScan Therapeutics (NASDAQ:TCRX)Wedbush restated an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a report on Wednesday.March 6, 2025 | marketbeat.comNeedham & Company LLC Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $9.00Needham & Company LLC decreased their price objective on shares of TScan Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a report on Wednesday.March 6, 2025 | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Issues Quarterly Earnings ResultsTScan Therapeutics (NASDAQ:TCRX - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%.March 6, 2025 | marketbeat.comTScan Therapeutics reports Q4 EPS (30c), consensus (28c)March 6, 2025 | markets.businessinsider.comTScan Therapeutics files $300M mixed securities shelfMarch 6, 2025 | markets.businessinsider.comTScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 5, 2025 | globenewswire.comTScan Therapeutics (NASDAQ:TCRX) Stock Price Down 11.9% - Here's What HappenedTScan Therapeutics (NASDAQ:TCRX) Trading Down 11.9% - Here's WhyMarch 4, 2025 | marketbeat.comTScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.comTScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceFebruary 18, 2025 | globenewswire.comTScan Therapeutics: Finding Their Footing After An Eventful ASH MeetingFebruary 10, 2025 | seekingalpha.comabrdn plc Has $2.69 Million Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX)abrdn plc increased its position in TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 137.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 883,704 shares of the company's stock after buying an additional 512,049 shares during the period.February 10, 2025 | marketbeat.comTScan Therapeutics Insider Ups Holding By 18% During YearFebruary 5, 2025 | finance.yahoo.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Down 20.6% in JanuaryTScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 2,000,000 shares, a decrease of 20.6% from the December 31st total of 2,520,000 shares. Approximately 4.6% of the company's shares are sold short. Based on an average daily volume of 403,800 shares, the days-to-cover ratio is currently 5.0 days.February 1, 2025 | marketbeat.comBarclays Sticks to Its Buy Rating for TScan Therapeutics (TCRX)January 16, 2025 | markets.businessinsider.comTScan Therapeutics' SWOT analysis: innovative t-cell therapy stock faces pivotal yearJanuary 16, 2025 | msn.comTScan Shares Jump 23% on Securities Purchase AgreementDecember 26, 2024 | marketwatch.comTScan Therapeutics To Offer $30 Mln Pre-funded Warrants At 37% PremiumDecember 26, 2024 | markets.businessinsider.comTScan Therapeutics announces $30M registered direct offeringDecember 26, 2024 | markets.businessinsider.comTScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% PremiumDecember 26, 2024 | globenewswire.comWith 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backingDecember 25, 2024 | finance.yahoo.comWith 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backingDecember 25, 2024 | finance.yahoo.comTScan Therapeutics refinances existing convertible debt facilityDecember 23, 2024 | markets.businessinsider.comTScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley BankDecember 23, 2024 | globenewswire.comWedbush Has Pessimistic Outlook of TCRX FY2026 EarningsTScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Investment analysts at Wedbush dropped their FY2026 earnings per share estimates for TScan Therapeutics in a research report issued to clients and investors on Tuesday, December 10th. Wedbush analyst D. Nierengarten now forecasts that the comDecember 13, 2024 | marketbeat.comTScan Therapeutics: Promising Phase I ALLOHA Trial Results and Future Pivotal Study Drive Buy RatingDecember 12, 2024 | markets.businessinsider.comTScan Therapeutics’ TSC-101: Strong Buy Rating on Promising Clinical and Market PotentialDecember 11, 2024 | markets.businessinsider.comPromising Potential for TScan Therapeutics: Buy Rating Affirmed on Strong Clinical Data and Strategic InitiativesDecember 11, 2024 | markets.businessinsider.comPromising Trial Results and Safety Profile Justify Buy Rating for TScan TherapeuticsDecember 11, 2024 | markets.businessinsider.comThe Analyst Landscape: 5 Takes On TScan TherapeuticsDecember 11, 2024 | benzinga.comTScan Therapeutics (NASDAQ:TCRX) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $11.00 target price on shares of TScan Therapeutics in a research note on Wednesday.December 11, 2024 | marketbeat.com Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRX Media Mentions By Week TCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TCRX News Sentiment▼0.150.49▲Average Medical News Sentiment TCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TCRX Articles This Week▼12▲TCRX Articles Average Week Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mereo BioPharma Group News Today Benitec Biopharma News Today Aura Biosciences News Today Cryoport News Today Cartesian Therapeutics News Today 2seventy bio News Today Aquestive Therapeutics News Today Taysha Gene Therapies News Today Astria Therapeutics News Today Atyr PHARMA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TCRX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our Partners🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TCRX Stock Free TCRX Stock Alerts